CFN Media today released an exclusive interview with Eric Adams, CEO of InMed Pharmaceuticals.
It is a very interesting discussion about the companies recent research, and the implications that it could have on the cannabis biosynthesis industry as a whole.
As you know, we've been championing InMed as a potential big winner in the cannabis biosynthesis space, due to their proprietary biosynthesis process, the results they've already been announcing, and the strong management and advisory team they have put in place. If you are interested in InMed, we recommend giving this video a watch.
FROM CFN:
The cannabis industry is projected to reach $50 billion in size by 2026, but the pharmaceutical side of the industry could become even larger. While new discoveries have already shown tremendous promise, the industry faces many challenges when it comes to developing and scaling the production of cannabinoid therapeutics. Fortunately, there are some companies that aim to solve these issues, including InMed Pharmaceuticals Inc. (CSE: IN) (OTCQB: IMLFF).
Watch CFN Media’s recent interview with InMed President and CEO Eric A. Adams. Mr. Adams discusses the company’s recent research results and their significance for both InMed and the canna-pharmaceutical industry in general.
READ THE FULL ARTICLE FROM CFN MEDIA HERE
